Skip to main content

Table 2 Premenopausal estrogens and progesterone and breast cancer risk: Nurses' Health Study II, 1999 to 2009

From: Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II

 

1st Quintile

2nd Quintile

3rd Quintile

4th Quintile

5th Quintile

 
 

OR (95% CI)

OR (95% CI)

OR (95% CI)

OR (95% CI)

OR (95% CI)

P trend

FOLLICULAR

      

Estradiol

      

   Cutpoints, pg/mL

< 29

≥ 29 to 40.9

≥ 41 to 51.9

≥ 52 to 73.9

≥ 74

 

   No. cases/No. controls*

84/179

93/183

84/179

109/186

92/182

 

   All cancers

1.0 (referent)

1.1 (0.7 to 1.6)

1.0 (0.7 to 1.5)

1.2 (0.8 to 1.7)

1.0 (0.7 to 1.5)

0.76

   Invasive

1.0 (referent)

1.2 (0.8 to 1.8)

1.0 (0.6 to 1.6)

1.4 (0.9 to 2.1)

1.0 (0.7 to 1.6)

0.70

   ER+/PR+

1.0 (referent)

1.1 (0.7 to 1.8)

0.9 (0.5 to 1.5)

1.5 (0.9 to 2.4)

1.0 (0.6 to 1.6)

0.68

   In situ

1.0 (referent)

1.0 (0.5 to 1.8)

1.1 (0.6 to 1.9)

0.8 (0.5 to 1.5)

1.1 (0.6 to 2.0)

0.81

Free estradiol

      

   Cutpoints, pg/mL

< 0.39

≥ 0.39 to 0.519

≥ 0.52 to 0.669

≥ 0.67 to 0.909

≥ 0.91

 

   No. cases/No. controls

90/178

80/175

104/179

96/176

77/178

 

   All cancers

1.0 (referent)

0.9 (0.6 to 1.4)

1.1 (0.7 to 1.5)

1.1 (0.8 to 1.7)

0.8 (0.5 to 1.2)

0.48

   Invasive

1.0 (referent)

1.0 (0.6 to 1.5)

1.0 (0.6 to 1.5)

1.2 (0.8 to 1.9)

0.8 (0.5 to 1.2)

0.50

   ER+/PR+

1.0 (referent)

1.1 (0.7 to 1.9)

1.2 (0.7 to 2.0)

1.3 (0.8 to 2.1)

0.7 (0.4 to 1.2)

0.35

   In situ

1.0 (referent)

0.9 (0.5 to 1.7)

1.2 (0.7 to 2.1)

0.8 (0.5 to 1.6)

0.9 (0.5 to 1.7)

0.77

Estrone

      

   Cutpoints, pg/mL

< 30

≥ 30 to 36.9

≥ 37 to 43.9

≥ 44 to 55.9

≥ 56

 

   No. cases/No. controls

93/184

86/192

91/176

111/184

88/184

 

   All cancers

1.0 (referent)

0.9 (0.6 to 1.2)

1.0 (0.7 to 1.4)

1.2 (0.8 to 1.7)

1.0 (0.7 to 1.4)

0.62

   Invasive

1.0 (referent)

0.8 (0.5 to 1.3)

1.1 (0.7 to 1.7)

1.1 (0.7 to 1.7)

0.9 (0.6 to 1.3)

0.92

   ER+/PR+

1.0 (referent)

1.2 (0.7 to 2.0)

1.3 (0.8 to 2.2)

1.6 (1.0 to 2.7)

1.2 (0.7 to 2.0)

0.32

   In situ

1.0 (referent)

1.1 (0.6 to 2.0)

0.8 (0.4 to 1.5)

1.5 (0.8 to 2.6)

1.3 (0.7 to 2.3)

0.22

LUTEAL

      

Estradiol

      

   Cutpoints, pg/mL

< 91

≥ 91 to 116.9

≥ 117/146.9

≥ 147 to 186.9

≥ 187

 

   No. cases/No. controls

90/197

72/187

123/187

113/195

81/193

 

   All cancers

1.0 (referent)

0.8 (0.6 to 1.3)

1.5 (1.0 to 2.2)

1.3 (0.9 to 1.9)

0.9 (0.6 to 1.4)

0.65

   Invasive

1.0 (referent)

1.0 (0.6 to 1.6)

1.9 (1.3 to 2.9)

1.5 (1.0 to 2.3)

1.3 (0.8 to 2.0)

0.08

   ER+/PR+

1.0 (referent)

1.2 (0.7 to 2.2)

2.5 (1.5 to 4.2)

1.9 (1.1 to 3.2)

1.7 (1.0 to 2.9)

0.02

   In situ

1.0 (referent)

0.6 (0.3 to 1.2)

1.1 (0.6 to 1.9)

1.0 (0.6 to 1.7)

0.5 (0.3 to 0.9)

0.17

Free estradiol

      

   Cutpoints, pg/mL

< 1.20

≥ 1.20 to 1.49

≥ 1.50 to 1.89

≥ 1.90 to 2.39

≥ 2.40

 

   No. cases/No. controls

94/188

95/190

93/188

100/189

87/189

 

   All cancers

1.0 (referent)

1.1 (0.7 to 1.6)

1.0 (0.7 to 1.5)

1.1 (0.8 to 1.6)

1.0 (0.7 to 1.5)

0.99

   Invasive

1.0 (referent)

1.2 (0.8 to 1.8)

1.3 (0.9 to 2.0)

1.2 (0.8 to 1.9)

1.2 (0.8 to 1.9)

0.36

   ER+/PR+

1.0 (referent)

1.3 (0.8 to 2.2)

1.5 (0.9 to 2.6)

1.5 (0.9 to 2.6)

1.3 (0.7 to 2.1)

0.28

   In situ

1.0 (referent)

0.9 (0.5 to 1.5)

0.6 (0.3 to 1.1)

0.8 (0.5 to 1.5)

0.7 (0.4 to 1.4)

0.32

Estrone

      

   Cutpoints, pg/mL

< 61

≥ 61 to 74.9

≥ 75 to 91.9

≥ 92 to 113.9

≥ 114

 

   No. cases/No. controls

121/198

84/201

90/206

92/201

113/199

 

   All cancers

1.0 (referent)

0.7 (0.5 to 1.0)

0.8 (0.5 to 1.1)

0.8 (0.5 to 1.1)

0.9 (0.7 to 1.3)

0.89

   Invasive

1.0 (referent)

0.7 (0.5 to 1.1)

0.8 (0.5 to 1.2)

0.8 (0.5 to 1.1)

1.1 (0.7 to 1.6)

0.67

   ER+/PR+

1.0 (referent)

0.5 (0.3 to 0.8)

0.8 (0.5 to 1.2)

0.8 (0.5 to 1.3)

0.9 (0.6 to 1.5)

0.87

   In situ

1.0 (referent)

0.7 (0.4 to 1.2)

0.8 (0.4 to 1.3)

0.8 (0.5 to 1.4)

0.8 (0.4 to 1.3)

0.55

Progesterone

      

   Cutpoints, ng/dL

< 743

≥ 743 to 1202.9

≥ 1203 to 1600.9

≥ 1601 to 2170.9

≥ 2171

 

   No. cases/No. controls

113/204

82/199

86/204

113/200

107/202

 

   All cancers

1.0 (referent)

0.7 (0.4 to 1.0)

0.8 (0.5 to 1.1)

1.0 (0.7 to 1.4)

0.9 (0.6 to 1.4)

0.82

   Invasive

1.0 (referent)

0.7 (0.4 to 1.0)

0.7 (0.5 to 1.1)

1.0 (0.7 to 1.5)

1.0 (0.6 to 1.5)

0.91

   ER+/PR+

1.0 (referent)

0.6 (0.4 to 1.0)

0.7 (0.4 to 1.1)

1.0 (0.6 to 1.6)

0.9 (0.6 to 1.5)

0.74

   In situ

1.0 (referent)

0.7 (0.4 to 1.2)

0.8 (0.4 to 1.4)

0.8 (0.4 to 1.4)

0.8 (0.5 to 1.5)

0.43

  1. All cancers: Conditional logistic regression for all cancers controlling for age at menarche, parity/age at first birth, BMI at age 18, family history of breast cancer, history of benign breast disease. Invasive, ER+/PR+, in situ tumors: Unconditional logistic regression for invasive, ER+/PR+, and in situ disease controlling for factors listed above and matching factors. *No. cases/No. controls are for all cancers; Overall No. cases/No. controls for invasive and ER+/PR+ cancers are in Table 4.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us